Teladoc Health (NYSE:TDOC) Releases Q2 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its second quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of -0.300–0.200 for the period, compared to the consensus estimate of -0.220. The company issued revenue guidance of $597.0 million-$626.0 million, compared to the consensus revenue estimate of $623.9 million. Teladoc Health also updated its FY 2026 guidance to -1.050–0.750 EPS.

Teladoc Health Price Performance

Shares of TDOC traded down $0.05 during trading hours on Wednesday, hitting $5.95. 4,904,611 shares of the company were exchanged, compared to its average volume of 5,909,743. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -5.22 and a beta of 2.07. Teladoc Health has a fifty-two week low of $4.40 and a fifty-two week high of $9.77. The company has a quick ratio of 2.67, a current ratio of 2.77 and a debt-to-equity ratio of 0.72. The firm’s fifty day moving average is $5.35 and its 200 day moving average is $6.47.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.02). The company had revenue of $613.85 million for the quarter, compared to analyst estimates of $613.82 million. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, equities analysts anticipate that Teladoc Health will post -0.89 earnings per share for the current fiscal year.

Analyst Ratings Changes

TDOC has been the topic of several research analyst reports. Oppenheimer reduced their price objective on Teladoc Health from $12.00 to $7.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a research note on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Teladoc Health in a research note on Friday, March 27th. Bank of America raised Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Thursday, February 26th. Finally, JPMorgan Chase & Co. reduced their price objective on Teladoc Health from $9.00 to $7.00 and set a “neutral” rating on the stock in a research note on Friday, March 13th. Six research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Teladoc Health currently has an average rating of “Hold” and an average target price of $7.62.

Insider Activity at Teladoc Health

In other news, CEO Charles Divita III sold 27,731 shares of Teladoc Health stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19. Following the sale, the chief executive officer directly owned 364,784 shares of the company’s stock, valued at approximately $2,002,664.16. This trade represents a 7.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.70% of the company’s stock.

Institutional Trading of Teladoc Health

Hedge funds have recently made changes to their positions in the company. Entropy Technologies LP acquired a new stake in shares of Teladoc Health during the third quarter valued at about $133,000. Polymer Capital Management US LLC acquired a new stake in shares of Teladoc Health during the third quarter valued at about $131,000. HighTower Advisors LLC raised its position in shares of Teladoc Health by 19.2% during the fourth quarter. HighTower Advisors LLC now owns 18,647 shares of the health services provider’s stock worth $131,000 after acquiring an additional 2,997 shares during the last quarter. Martingale Asset Management L P bought a new position in shares of Teladoc Health during the fourth quarter worth about $116,000. Finally, Manhattan West Asset Management LLC bought a new position in shares of Teladoc Health during the second quarter worth about $100,000. 76.82% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.